You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.
Footnotes
-
Citation: R. Sikorski, B. Yao, Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution. Sci. Transl. Med. 1, 10ps11 (2009).
- Copyright © 2009, American Association for the Advancement of Science
